Emzor Pharmaceutical Industries Limited has renewed its strong commitment to eradicating malaria across Nigeria and Sub-Saharan Africa, as the world marks World Malaria Day 2025.
Aligning with this year’s theme, “Malaria Ends With Us: Reinvest, Reimagine, Reignite,” Emzor highlighted its decades-long leadership in producing affordable, high-quality antimalarial drugs that have reached millions across the continent.
“For years, Emzor has stood at the forefront of the malaria fight,” said Mr. Kunle Faloye, Head of Marketing and Strategy at Emzor. “Our investments in research, production, and distribution have been critical in reducing the malaria burden.”
To commemorate the day, Emzor launched a series of impactful initiatives, including a health walk, free medical screenings, and widespread distribution of antimalarial medicines to vulnerable groups.
Malaria remains a leading cause of death among pregnant women and children under five in Africa.
In response, Emzor has intensified the production of over 20 antimalarial products, such as Maldox (Sulfadoxine/Pyrimethamine), Lokmal (Artemether/Lumefantrine), Piramal TS (Dihydroartemisinin/Piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, available in tablets, suspensions, and dispersible forms.
Taking its fight further, Emzor recently unveiled a multimillion-dollar Active Pharmaceutical Ingredients (API) manufacturing facility at its new Pharmaceutical Campus in Sagamu, Ogun State. The factory will focus on producing critical antimalarial APIs — Artemether, Lumefantrine, Sulfadoxine, and Pyrimethamine — used in WHO-recommended treatments.
This landmark project not only strengthens Nigeria’s pharmaceutical independence but also reduces reliance on drug imports, boosts GDP, conserves foreign exchange, and lowers treatment costs for millions at risk.
“With 95% of malaria cases and 96% of malaria deaths occurring in Africa, the solution must come from within,” said Mr. Emeka Okoli, Chairman of Emzor’s Board of Directors. “Our API project is a game-changer for Africa’s health sovereignty.”
Beyond manufacturing, Emzor collaborates with governments, NGOs, and local communities to promote grassroots education, prevention, diagnosis, and treatment initiatives.
It also continues to supply free and subsidized medications to pregnant women and children — the most vulnerable groups.
“As we observe this critical day, Emzor remains firmly committed to investing in sustainable, innovative healthcare solutions that transform lives across Nigeria and Africa,” added Mr. Faloye.
